Norgine and SpePharm Holding Enter Into Joint Venture

Norgine and SpePharm Holding Enter Into Joint Venture PR Newswire AMSTERDAM, December 18, 2012 AMSTERDAM, December 18, 2012 /PRNewswire/ -- Norgine BV (Amsterdam) and SpePharm Holding BV (Amsterdam) announced today that they have concluded a broad collaboration agreement under which the two companies have invested in a 50:50 joint venture, SpePharm AG, which ® ® ® ®has acquired the entire product portfolio of SpePharm Holding, including Savene , MuGard , Xerotin , PROther and ®the Dantrium brands. The new joint venture will commercialise this entire product portfolio through Norgine's pharmaceutical infrastructure, which spans all of the major markets of Europe. SpePharm AG will seek to acquire further hospital based products which will also be sold through Norgine's commercial infrastructure. Financial terms were not disclosed. http://photos.prnewswire.com/prnh/20121218/582961-a http://photos.prnewswire.com/prnh/20121218/582961-b As a consequence of the transactions, TVM Capital and Signet Healthcare Partners announced that SpePharm has repaid all of its existing debt facilities and the two firms have acquired all shares previously owned by the debt providers. Finally, Norgine BV has acquired the commercial subsidiaries of SpePharm Holding BV in Italy, Germany, the Nordics and the UK. These acquisitions will enable Norgine to enlarge its existing European commercial infrastructure and to fully support the combined product portfolio.